Abstract
Key Points The Impella percutaneous microaxial ventricular assist device provides significant ventricular unloading, but at the cost of increased major bleeding, hemolysis, and thrombocytopenia. The present study shows that nearly all patients develop thrombocytopenia within 7 days of Impella insertion with 81% having a >50% decrease. Platelet recovery occurs following device removal. Recognition of Impella‐related thrombocytopenia can reduce the concern for heparin‐induced thrombocytopenia and avoid the potential risks of direct thrombin inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
